Brought to you by 
Partner Therapeutics acquires Sanofi's immunostimulant Leukine
03 Jan 2022
Executive Summary
Recently launched Partner Therapeutics Inc. (PTx; oncology) has commenced operations by acquiring the immunostimulant Leukine (sargramostim) from Sanofi for an undisclosed sum.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com